VivoSeq
Other

Tacrolimus

0

Pipeline Programs↗

2

Active Trials↗

8

Companies Involved↗

Tacrolimus is an early-stage landscape with 0 programs across 8 companies. The most active players are Astellas, LEO Pharma, Auritec Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

96/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Astellas logo

Astellas

0 programs

PreclinicalLEO Pharma logo

LEO Pharma

0 programs

PreclinicalA

Auritec Pharmaceuticals

0 programs

PreclinicalTibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland

0 programs

PreclinicalV

Veloxis Pharmaceuticals

0 programs

PreclinicalVertex Pharmaceuticals logo

Vertex Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

57

clinical trials

Completed43 · 75%
Unknown status10 · 18%
Withdrawn2 · 4%
Recruiting2 · 4%

Clinical Trials

Trial Activity

57 trials

Tacrolimus and Personalized Therapy to Prevent Acute Rejection Episodes
Recruiting·FFondazione IRCCS Policlinico San Matteo di Pavia·N/A·NCT06338306·25 enrolled
Tacrolimus Pharmacokinetic Subpopulations
Recruiting·UUniversity Hospital, Grenoble·N/A·NCT04526431·180 enrolled
Tacrolimus Blood Levels After Topical Application of Tacrolimus on Healthy Skin
Completed·LEO Pharma logoLEO Pharma·Phase 1·NCT03673527·24 enrolled
Tacrolimus Toothpaste for Management of Oral Chronic Graft vs. Host Disease (cGVHD)
Completed·—·Phase 1·NCT06638879·7 enrolled
Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics
Completed·LLI YAN·N/A·NCT06044558·507 enrolled
Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops
Completed·UUniversity of Sao Paulo General Hospital·Phase 4·NCT01850979·24 enrolled
Comparison of Two Tacrolimus Based Immunosuppressive Regimens in Recipients Receiving Marginal Donor Kidneys
Completed·Astellas logoAstellas·Phase 3·NCT00321113·142 enrolled
Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients
Completed·MMayo Clinic·Phase 4·NCT04041219·10 enrolled
Diabetogenicity of Cyclosporine and Tacrolimus
Completed·UUniversity of Aarhus·Phase 4·NCT00766909·18 enrolled
OPTImization of the Dose of tacroliMUS by Bayesian Prediction
Completed·NNURIA LLOBERAS BLANCH·Phase 4·NCT03465410·96 enrolled
Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fed Condition
Completed·PPanacea Biotec Ltd·N/A·NCT01080469·36 enrolled
Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study
Completed·AAuritec Pharmaceuticals·Phase 1·NCT03626714·8 enrolled
Pharmacokinetic Studies of Tacrolimus in Transplant Patients
Completed·UUniversity of Cincinnati·Phase 4·NCT01889758·78 enrolled
CNS Study of Patients Switching From Tacrolimus to Envarsus
Completed·UUniversity of Colorado, Denver·Phase 4·NCT03270462·20 enrolled
Bioequivalence Study of Tacrolimus 1 mg Capsule Under Fasting Condition
Completed·PPanacea Biotec Ltd·N/A·NCT01080456·36 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)